We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

356 hedge funds and large institutions have $15.8B invested in Alnylam Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 125 increasing their positions, 129 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 129

5% less capital invested

Capital invested by funds: $16.5B → $15.8B (-$744M)

7% less call options, than puts

Call options by funds: $121M | Put options by funds: $131M

3.68% less ownership

Funds ownership: 97.24% → 93.55% (-3.7%)

5% less funds holding

Funds holding: 374 → 356 (-18)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

35% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 49

Holders
356
Holders Change
-18
Holders Change %
-4.81%
% of All Funds
7.18%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.14%
New
32
Increased
125
Reduced
129
Closed
49
Calls
$121M
Puts
$131M
Net Calls
-$9.8M
Net Calls Change
-$52.2M

Top Buyers

1
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$120M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$34.5M
3
FCM
Farallon Capital Management
California
+$21.3M
4
Norges Bank
Norges Bank
Norway
+$19.6M
5
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$10.6M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$86.1M
2
Goldman Sachs
Goldman Sachs
New York
-$70.7M
3
SPC
Slate Path Capital
New York
-$52.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$52.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$47.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
LFG
401
LifePlan Financial Group
Ohio
– +$284 +2 New
MCM
402
Manchester Capital Management
Vermont
– +$426 +3 New
13 14 15 16
17

ALNY Hedge Fund Activity: Q3 2020 in Review

356 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2020, worth a combined $15.8B — down 4.5% from $16.5B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ALNY and 32 opened new positions — a net loss of 17 holders — while 129 trimmed existing stakes and 125 added.

The largest buyer was Massachusetts Financial Services, adding an estimated $120M. The largest seller was Fidelity Investments, cutting an estimated $86.1M.

  • 356 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2020, down from 374 in Q2 2020.
  • Funds reported $15.8B of Alnylam Pharmaceuticals stock for Q3 2020, down 4.5% quarter-over-quarter.
  • 32 funds opened new Alnylam Pharmaceuticals positions in Q3 2020 and 49 closed out, a net change of -17 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2020 was Massachusetts Financial Services, an estimated $120M added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $86.1M sold.

Based on aggregated 13F filings for Q3 2020.